Hemophilia and Gene Therapy
Summary
TLDRHemophilia is a genetic disorder affecting blood clotting, leading to prolonged bleeding and potential internal damage. It is caused by defective genes responsible for clotting factors, with Hemophilia A and B linked to deficiencies in factors 8 and 9, respectively. Current treatments involve lifelong clotting factor replacement therapy. Gene therapy offers a potential one-time treatment, where a functional gene is delivered to liver cells to produce the missing clotting factor. Clinical trials are ongoing, with a focus on adult patients to ensure long-term efficacy.
Takeaways
- đ©ž Hemophilia is a rare genetic disorder affecting the blood's ability to clot, leading to prolonged bleeding.
- 𧏠It occurs due to defects in genes responsible for producing clotting factors, which are proteins essential for stopping bleeding.
- đ There are 12 defined clotting factors, with Hemophilia A and B caused by deficiencies in clotting factors 8 and 9, respectively.
- đ The most common treatment is clotting factor replacement therapy, administered through infusions for the patient's entire life.
- 𧏠Gene therapy is an emerging treatment that delivers a functional version of the defective gene into cells to produce the missing clotting factor.
- đ A vector, often derived from viruses but modified to carry therapeutic genes, is used to deliver the functional gene into the cells.
- đ For treating Hemophilia A and B, the vector targets liver cells, which are responsible for producing clotting factors E and 9.
- đ± The liver's role is crucial as it grows with the individual, maintaining the effectiveness of the therapy as it matures.
- đ§Ș Gene therapy trials are currently focused on adults with hemophilia to ensure the therapy's benefits do not diminish with age.
- đ Researchers are optimistically monitoring the progress of gene therapies in clinical trials for their safety and efficacy.
- đ Individuals with hemophilia should consult with a hematologist or a hemophilia treatment center for information on gene therapy options.
Q & A
What is hemophilia?
-Hemophilia is a rare genetic disorder that prevents blood from clotting properly, leading to prolonged external bleeding and potentially dangerous internal bleeding.
What are the consequences of internal bleeding in hemophilia?
-Internal bleeding in hemophilia can be incredibly dangerous, causing deep bleeding inside joints and muscles, which can lead to permanent disability or be life-threatening, especially when organs are damaged.
How many clotting factors are there in the blood?
-There are 12 defined clotting factors in the blood that help the body to stop bleeding.
What is the difference between hemophilia A and hemophilia B?
-Hemophilia A is caused by a mutation in the gene that creates a deficient amount of clotting factor 8, while hemophilia B is caused by a deficiency in clotting factor 9.
What is the most common treatment for hemophilia?
-The most common treatment for hemophilia is clotting factor replacement therapy, which involves administering the clotting factor into the bloodstream through an infusion.
What is gene therapy and how could it treat hemophilia?
-Gene therapy is a one-time treatment that delivers a functional version of the missing or defective gene into a cell to produce the missing clotting factor. It uses a vector, often derived from viruses, to deliver the functional genes into the cells.
Why is the liver an important organ in treating hemophilia with gene therapy?
-The liver is important because it is responsible for creating a variety of elements in the blood, including clotting factors. By introducing a vector containing the functional gene to liver cells, the liver can produce and secrete functionally active clotting factors back into the blood.
Why are gene therapy trials being conducted in adults with hemophilia?
-Gene therapy trials are conducted in adults to avoid the beneficial effects of the therapy from becoming weaker or wearing off as a child's liver grows with age.
Can standard of care treatments still be used if bleeding occurs during or after gene therapy?
-Yes, if bleeding occurs during or after gene therapy, the use of any standard of care treatment can still be used.
What should an individual with hemophilia do to learn more about gene therapy options?
-An individual with hemophilia should carefully discuss gene therapy options with their hematologist or hemophilia treatment center and visit resources like ASGCT.org for more information.
How does gene therapy work in the context of hemophilia treatment?
-Gene therapy for hemophilia works by targeting the liver cells via infusion with a vector containing the functional gene. This allows the liver to produce the necessary clotting factors to prevent bleeding.
Outlines
đ©ž Hemophilia: A Genetic Clotting Disorder
Hemophilia is a rare genetic disorder that affects the blood's ability to clot, leading to prolonged bleeding, spontaneous bruises, and internal bleeding that can be dangerous or even life-threatening, particularly when it affects organs. The disorder arises from defective genes responsible for producing clotting factors, with hemophilia A and B being the most common types, each caused by a deficiency in specific clotting factors. The traditional treatment involves lifelong clotting factor replacement therapy administered through infusions.
𧏠Gene Therapy: A Potential Cure for Hemophilia
Gene therapy presents a one-time treatment option for hemophilia by delivering a functional version of the missing or defective gene into cells to produce the necessary clotting factors. This is achieved using a vector, often a modified virus, engineered to deliver therapeutic genes without any viral genes. The liver plays a crucial role in this process, as it is responsible for creating clotting factors, and the vector is targeted to liver cells to enable the production and secretion of active clotting factors into the bloodstream. Gene therapy trials are currently focusing on adults to ensure the treatment's effectiveness as the liver grows with age.
đŹ Ongoing Clinical Trials and Standard Care
Clinical trials for gene therapy in hemophilia are ongoing, with researchers optimistically monitoring their progress. These trials aim to safely and effectively prevent bleeding episodes by compensating for the clotting factor deficiency. It is important to note that if bleeding occurs during or after gene therapy, standard care treatments can still be applied. Individuals with hemophilia should consult with a hematologist or a hemophilia treatment center to discuss gene therapy options and to access more information and resources about this emerging treatment.
Mindmap
Keywords
đĄHemophilia
đĄClotting Factors
đĄGene Therapy
đĄVector
đĄLiver
đĄClotting Factor Replacement Therapy
đĄGenetic Disorder
đĄInternal Bleeding
đĄHemophilia A and B
đĄClinical Trials
đĄHematologist
Highlights
Hemophilia is a rare genetic disorder affecting blood clotting.
Prolonged bleeding can occur spontaneously or due to injury, dental work, or surgery.
Internal bleeding can be dangerous, leading to joint and muscle damage or organ damage.
Hemophilia A is caused by a mutation affecting clotting factor 8, while Hemophilia B is due to clotting factor 9 deficiency.
There are 12 defined clotting factors in the blood.
Existing treatments involve lifelong clotting factor replacement therapy.
Gene therapy could offer a one-time treatment for hemophilia.
Gene therapy involves delivering a functional gene into cells using a vector derived from viruses.
The liver plays a crucial role in creating clotting factors and is targeted for gene therapy.
Gene therapy trials are being conducted in eligible adults to avoid effects weakening as the liver grows.
The liver's growth from childhood to adulthood is considered in gene therapy trials.
Researchers are optimistically monitoring the progress of gene therapies in clinical trials.
Gene therapy aims to safely and effectively prevent bleeds by compensating for the clotting factor deficiency.
Standard of care treatments can still be used if bleeding occurs during or after gene therapy.
Individuals with hemophilia should discuss gene therapy options with a hematologist or treatment center.
More information about gene therapy for hemophilia can be found at ASGCT.org.
Transcripts
hemophilia is a rare genetic disorder
that prevents blood from clotting
properly as a result prolonged external
bleeding can occur spontaneously or due
to injury bruises dental work or surgery
internal bleeding can also be incredibly
dangerous for people with hemophilia
deep bleeding inside joints and muscles
can lead to permanent disability or may
be life-threatening
especially when damage occurs to organs
hemophilia occurs when the genes that
are vital to creating clotting factors
are defective clotting factors are
proteins in the blood that help our
bodies to stop bleeds there are 12
defined clotting factors hemophilia A is
caused by a mutation in the gene that
creates a deficient amount of clotting
factor 8 while hemophilia B is caused by
a deficiency in clotting factor nine
different deficiencies each caused by a
different genetic defect
the most common existing hemophilia
treatments administer clotting factor
replacement therapy into the bloodstream
through an infusion these treatments are
required throughout a person's entire
lifetime to prevent or treat bleeding
however gene therapy could offer a
one-time treatment with gene therapy a
functional version of the missing or
defective gene can be delivered into a
cell to produce the missing factor
functional genes need to be delivered
into the cells using a vector which is
often derived from viruses don't worry
all viral genes are removed and the
vector is engineered to only deliver
therapeutic genes to treat hemophilia A
and B the vector would be targeted to a
person's liver cells via infusion to
explain more about the livers role
here's dr. Denise sabbatino the liver is
an important organ that is responsible
for creating a variety of elements in
our blood
including clotting factors E and 9 in
individuals with hemophilia the genes
that produced these factors are
defective or absent by introducing a
vector containing the functional gene to
liver cells the liver can produce and
secrete functionally active clotting
factors back into the blood to prevent
fleas
since the liver grows with us from
childhood to adulthood gene therapy
trials are currently being conducted in
eligible adults with hemophilia this
helps to avoid the therapies beneficial
effects from becoming weaker or wearing
off as a child and their liver grows
with age researchers continue to
optimistically monitor gene therapies in
clinical trials until they can safely
and effectively prevent bleeds by making
up for the deficiency but if a bleep
does occur during or after receiving a
gene therapy it is important to know
that the use of any standard of care
treatment can still be used an
individual with hemophilia should
carefully discuss gene therapy options
with their hematologist or hemophilia
treatment center for more information
and resources about gene therapy for
hemophilia visit ASG C TV Norg
[Music]
Voir Plus de Vidéos Connexes
Hemophilia (Year of the Zebra)
Punnett Squares and Sex-Linked Traits (UPDATED)
Punnett Squares and Sex-Linked Traits (OLD VIDEO)
Gene Therapy -- The time is now: Nick Leschly at TEDxBoston
Example punnet square for sex-linked recessive trait | High school biology | Khan Academy
Beta-thalassemia - causes, symptoms, diagnosis, treatment, pathology
5.0 / 5 (0 votes)